Exogenous midkine administration prevents cardiac remodeling in pacing-induced congestive heart failure of rabbits

Masahide Harada, Mayumi Hojo, Kaichiro Kamiya, Kenji Kadomatsu, Toyoaki Murohara, Itsuo Kodama, Mitsuru Horiba

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Midkine (MK), a heparin-binding growth factor, has been shown to prevent cardiac remodeling after ischemic injury through its anti-apoptotic effect. Cell apoptosis is central to the pathophysiology of cardiac remodeling in congestive heart failure (CHF) of ischemic as well as non-ischemic origin. We hypothesized that MK exerts the anti-apoptotic cardioprotective effect in CHF of non-ischemic etiology. MK protein or vehicle (normal saline) was subcutaneously administered in tachycardia-induced CHF rabbits (right ventricular pacing, 350 beats/min, 4 weeks). The vehicle-treated rabbits (n = 19, control) demonstrated severe CHF and high mortality rate, whereas MK (n = 16) demonstrated a well-compensated state and a lower mortality rate. In echocardiography, left ventricular (LV) end-diastolic dimension decreased in MK versus control, whereas LV systolic function increased. In histological analysis (picrosirius red staining), MK decreased collagen deposition area compared with control. TUNEL staining showed that MK prevented cell apoptosis and minimized myocyte loss in the CHF rabbit ventricle, associated with activation of PI3-K/Akt signaling, producing a parallel decrease of Bax/Bcl-2 ratio. MK prevented progression of cardiac remodeling in the CHF rabbit, likely by activation of anti-apoptotic signaling. Exogenous MK application might be a novel therapeutic strategy for CHF due to non-ischemic origin.

Original languageEnglish
Pages (from-to)96-104
Number of pages9
JournalHeart and Vessels
Volume31
Issue number1
DOIs
Publication statusPublished - 01-01-2016

Fingerprint

Heart Failure
Rabbits
Apoptosis
Staining and Labeling
midkine
Mortality
In Situ Nick-End Labeling
Left Ventricular Function
Tachycardia
Muscle Cells
Echocardiography
Heparin
Intercellular Signaling Peptides and Proteins
Collagen
Wounds and Injuries
Proteins

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Harada, Masahide ; Hojo, Mayumi ; Kamiya, Kaichiro ; Kadomatsu, Kenji ; Murohara, Toyoaki ; Kodama, Itsuo ; Horiba, Mitsuru. / Exogenous midkine administration prevents cardiac remodeling in pacing-induced congestive heart failure of rabbits. In: Heart and Vessels. 2016 ; Vol. 31, No. 1. pp. 96-104.
@article{9531a8f0b39f49348a338554f401e7c5,
title = "Exogenous midkine administration prevents cardiac remodeling in pacing-induced congestive heart failure of rabbits",
abstract = "Midkine (MK), a heparin-binding growth factor, has been shown to prevent cardiac remodeling after ischemic injury through its anti-apoptotic effect. Cell apoptosis is central to the pathophysiology of cardiac remodeling in congestive heart failure (CHF) of ischemic as well as non-ischemic origin. We hypothesized that MK exerts the anti-apoptotic cardioprotective effect in CHF of non-ischemic etiology. MK protein or vehicle (normal saline) was subcutaneously administered in tachycardia-induced CHF rabbits (right ventricular pacing, 350 beats/min, 4 weeks). The vehicle-treated rabbits (n = 19, control) demonstrated severe CHF and high mortality rate, whereas MK (n = 16) demonstrated a well-compensated state and a lower mortality rate. In echocardiography, left ventricular (LV) end-diastolic dimension decreased in MK versus control, whereas LV systolic function increased. In histological analysis (picrosirius red staining), MK decreased collagen deposition area compared with control. TUNEL staining showed that MK prevented cell apoptosis and minimized myocyte loss in the CHF rabbit ventricle, associated with activation of PI3-K/Akt signaling, producing a parallel decrease of Bax/Bcl-2 ratio. MK prevented progression of cardiac remodeling in the CHF rabbit, likely by activation of anti-apoptotic signaling. Exogenous MK application might be a novel therapeutic strategy for CHF due to non-ischemic origin.",
author = "Masahide Harada and Mayumi Hojo and Kaichiro Kamiya and Kenji Kadomatsu and Toyoaki Murohara and Itsuo Kodama and Mitsuru Horiba",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s00380-014-0569-5",
language = "English",
volume = "31",
pages = "96--104",
journal = "Heart and Vessels",
issn = "0910-8327",
publisher = "Springer Japan",
number = "1",

}

Exogenous midkine administration prevents cardiac remodeling in pacing-induced congestive heart failure of rabbits. / Harada, Masahide; Hojo, Mayumi; Kamiya, Kaichiro; Kadomatsu, Kenji; Murohara, Toyoaki; Kodama, Itsuo; Horiba, Mitsuru.

In: Heart and Vessels, Vol. 31, No. 1, 01.01.2016, p. 96-104.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Exogenous midkine administration prevents cardiac remodeling in pacing-induced congestive heart failure of rabbits

AU - Harada, Masahide

AU - Hojo, Mayumi

AU - Kamiya, Kaichiro

AU - Kadomatsu, Kenji

AU - Murohara, Toyoaki

AU - Kodama, Itsuo

AU - Horiba, Mitsuru

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Midkine (MK), a heparin-binding growth factor, has been shown to prevent cardiac remodeling after ischemic injury through its anti-apoptotic effect. Cell apoptosis is central to the pathophysiology of cardiac remodeling in congestive heart failure (CHF) of ischemic as well as non-ischemic origin. We hypothesized that MK exerts the anti-apoptotic cardioprotective effect in CHF of non-ischemic etiology. MK protein or vehicle (normal saline) was subcutaneously administered in tachycardia-induced CHF rabbits (right ventricular pacing, 350 beats/min, 4 weeks). The vehicle-treated rabbits (n = 19, control) demonstrated severe CHF and high mortality rate, whereas MK (n = 16) demonstrated a well-compensated state and a lower mortality rate. In echocardiography, left ventricular (LV) end-diastolic dimension decreased in MK versus control, whereas LV systolic function increased. In histological analysis (picrosirius red staining), MK decreased collagen deposition area compared with control. TUNEL staining showed that MK prevented cell apoptosis and minimized myocyte loss in the CHF rabbit ventricle, associated with activation of PI3-K/Akt signaling, producing a parallel decrease of Bax/Bcl-2 ratio. MK prevented progression of cardiac remodeling in the CHF rabbit, likely by activation of anti-apoptotic signaling. Exogenous MK application might be a novel therapeutic strategy for CHF due to non-ischemic origin.

AB - Midkine (MK), a heparin-binding growth factor, has been shown to prevent cardiac remodeling after ischemic injury through its anti-apoptotic effect. Cell apoptosis is central to the pathophysiology of cardiac remodeling in congestive heart failure (CHF) of ischemic as well as non-ischemic origin. We hypothesized that MK exerts the anti-apoptotic cardioprotective effect in CHF of non-ischemic etiology. MK protein or vehicle (normal saline) was subcutaneously administered in tachycardia-induced CHF rabbits (right ventricular pacing, 350 beats/min, 4 weeks). The vehicle-treated rabbits (n = 19, control) demonstrated severe CHF and high mortality rate, whereas MK (n = 16) demonstrated a well-compensated state and a lower mortality rate. In echocardiography, left ventricular (LV) end-diastolic dimension decreased in MK versus control, whereas LV systolic function increased. In histological analysis (picrosirius red staining), MK decreased collagen deposition area compared with control. TUNEL staining showed that MK prevented cell apoptosis and minimized myocyte loss in the CHF rabbit ventricle, associated with activation of PI3-K/Akt signaling, producing a parallel decrease of Bax/Bcl-2 ratio. MK prevented progression of cardiac remodeling in the CHF rabbit, likely by activation of anti-apoptotic signaling. Exogenous MK application might be a novel therapeutic strategy for CHF due to non-ischemic origin.

UR - http://www.scopus.com/inward/record.url?scp=84952909332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952909332&partnerID=8YFLogxK

U2 - 10.1007/s00380-014-0569-5

DO - 10.1007/s00380-014-0569-5

M3 - Article

VL - 31

SP - 96

EP - 104

JO - Heart and Vessels

JF - Heart and Vessels

SN - 0910-8327

IS - 1

ER -